These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

36 related articles for article (PubMed ID: 14020890)

  • 1. Studies with the murine leukemogenic Rauscher virus. I. Chemotherapy studies with in vivo and in vitro assay systems.
    CHIRIGOS MA; RAUSCHER FJ; KAMEL IA; FANNING GR; GOLDIN A
    Cancer Res; 1963 Jun; 23():762-9. PubMed ID: 14020890
    [No Abstract]   [Full Text] [Related]  

  • 2. STUDIES WITH THE MURINE LEUKEMOGENIC RAUSCHER VIRUS. II. CHEMOTHERAPY OF VIRUS-INDUCED LYMPHOID LEUKEMIA.
    CHIRIGOS MA; RAUSCHER FJ; KAMEL IA; FANNING GR; GOLDIN A
    Cancer Res; 1963 Nov; 23():1646-50. PubMed ID: 14098904
    [No Abstract]   [Full Text] [Related]  

  • 3. CHEMOTHERAPY STUDIES WITH VIRUS-INDUCED LEUKEMIA IN MICE.
    GOLDIN A; GLYNN JP; MOLONEY JB; HUMPHREYS SR; CHIRIGOS MA
    Acta Unio Int Contra Cancrum; 1964; 20():157-61. PubMed ID: 14151874
    [No Abstract]   [Full Text] [Related]  

  • 4. STUDIES WITH THE MURINE LEUKEMOGENIC RAUSCHER VIRUS. 3. AN IN VIVO ASSAY FOR ANTI-VIRAL AGENTS.
    CHIRIGOS MA
    Cancer Res; 1964 Jul; 24():1035-41. PubMed ID: 14198243
    [No Abstract]   [Full Text] [Related]  

  • 5. Biological interrelationships in the chemotherapy of Moloney virus leukemia.
    GLYNN JP; MOLONEY JB; CHIRIGOS MA; HUMPHREYS SR; GOLDIN A
    Cancer Res; 1963 Feb; 23():269-78. PubMed ID: 13948556
    [No Abstract]   [Full Text] [Related]  

  • 6. Electron microscopic and bioassay studies on a murine leukemia virus (Rauscher): preliminary report.
    ZEIGEL RF; RAUSCHER FJ
    J Natl Cancer Inst; 1963 Jan; 30():207-19. PubMed ID: 14003381
    [No Abstract]   [Full Text] [Related]  

  • 7. FLUORESCENT ANTIBODY STUDIES OF THE VIRAL ANTIGEN IN A MURINE LEUKEMIA (RAUSCHER).
    FINK MA; MALMGREN RA
    J Natl Cancer Inst; 1963 Nov; 31():1111-21. PubMed ID: 14071824
    [No Abstract]   [Full Text] [Related]  

  • 8. Inhibition of CFU-E/BFU-E and CFU-GM colony growth by cyclophosphamide, 5-fluorouracil and taxol: development of a high-throughput in vitro method.
    Malerba I; Casati S; Diodovich C; Parent-Massin D; Gribaldo L
    Toxicol In Vitro; 2004 Jun; 18(3):293-300. PubMed ID: 15046776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphism of the DNA repair enzyme XRCC1 is associated with treatment prediction in anthracycline and cyclophosphamide/methotrexate/5-fluorouracil-based chemotherapy of patients with primary invasive breast cancer.
    Jaremko M; Justenhoven C; Schroth W; Abraham BK; Fritz P; Vollmert C; Illig T; Simon W; Schwab M; Brauch H
    Pharmacogenet Genomics; 2007 Jul; 17(7):529-38. PubMed ID: 17558308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5.
    Levine MN; Pritchard KI; Bramwell VH; Shepherd LE; Tu D; Paul N;
    J Clin Oncol; 2005 Aug; 23(22):5166-70. PubMed ID: 16051958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group.
    Knoop AS; Knudsen H; Balslev E; Rasmussen BB; Overgaard J; Nielsen KV; Schonau A; Gunnarsdóttir K; Olsen KE; Mouridsen H; Ejlertsen B;
    J Clin Oncol; 2005 Oct; 23(30):7483-90. PubMed ID: 16234514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102.
    Hutchins LF; Green SJ; Ravdin PM; Lew D; Martino S; Abeloff M; Lyss AP; Allred C; Rivkin SE; Osborne CK
    J Clin Oncol; 2005 Nov; 23(33):8313-21. PubMed ID: 16293862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lessons from the initial adjuvant cyclophosphamide, methotrexate, and fluorouracil studies in operable breast cancer.
    Bonadonna G; Valagussa P; Veronesi U
    J Clin Oncol; 2008 Jan; 26(3):342-4. PubMed ID: 18202404
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group.
    Bonneterre J; Roché H; Kerbrat P; Fumoleau P; Goudier MJ; Fargeot P; Montcuquet P; Clavère P; Barats JC; Monnier A; Veyret C; Datchary J; Van Praagh I; Chapelle-Marcillac I
    J Clin Oncol; 2004 Aug; 22(15):3070-9. PubMed ID: 15284257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alkaline comet assay study with breast cancer patients: evaluation of baseline and chemotherapy-induced DNA damage in non-target cells.
    Kopjar N; Milas I; Garaj-Vrhovac V; Gamulin M
    Clin Exp Med; 2006 Dec; 6(4):177-90. PubMed ID: 17191110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo targeting of dead tumor cells in a murine tumor model using a monoclonal antibody specific for the La autoantigen.
    Al-Ejeh F; Darby JM; Pensa K; Diener KR; Hayball JD; Brown MP
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5519s-5527s. PubMed ID: 17875784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide.
    Lun XQ; Jang JH; Tang N; Deng H; Head R; Bell JC; Stojdl DF; Nutt CL; Senger DL; Forsyth PA; McCart JA
    Clin Cancer Res; 2009 Apr; 15(8):2777-88. PubMed ID: 19351762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitoxantrone-cyclophosphamide-fluorouracil-combination chemotherapy in metastatic breast cancer. 3-Year-follow-up.
    Büyükünal E; Derman U; Serdengeçti S; Berkarda B
    J Chemother; 1989 Jul; 1(4 Suppl):1201-2. PubMed ID: 16312833
    [No Abstract]   [Full Text] [Related]  

  • 19. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
    Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF
    Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality of life in women with breast cancer during the first year after random assignment to adjuvant treatment with marrow-supported high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin or tailored therapy with Fluorouracil, epirubicin, and cyclophosphamide: Scandinavian Breast Group Study 9401.
    Brandberg Y; Michelson H; Nilsson B; Bolund C; Erikstein B; Hietanen P; Kaasa S; Nilsson J; Wiklund T; Wilking N; Bergh J;
    J Clin Oncol; 2003 Oct; 21(19):3659-64. PubMed ID: 14512398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 2.